Table 2.
Baseline Characteristics of Participants According to Sexual Activity Status
| Characteristic | Overall n=1255 |
Sexually Active n=857 (68.3%) |
Not Sexually Active n=398 (31.7%) |
p-value* |
|---|---|---|---|---|
| Demographic | ||||
| Age (yrs.)a | 66.9 (9.7) | 65.0 (9.0) | 70.9 (10.0) | <.0001 |
| Race/Ethnicity b | 0.003 | |||
| Non-Hispanic White b | 59.6 | 57.3 | 64.6 | |
| African-American b | 27.7 | 30.8 | 20.9 | |
| Hispanic b | 11.1 | 10.3 | 12.8 | |
| Other b | 1.7 | 1.6 | 1.8 | |
| Education b | 0.001 | |||
| Less than High School b | 8.1 | 6.4 | 11.6 | |
| High School Graduate/GED b | 15.7 | 14.4 | 18.6 | |
| Post High School b | 35.5 | 37.3 | 31.4 | |
| College Degree b | 40.8 | 41.9 | 38.4 | |
| Lives with Others b | 75.8 | 77.9 | 71.4 | 0.012 |
| Behavioral Risk Factors | ||||
| Smoking (pack-yrs.) § | 3.8 (0, 23) | 3.8 (0, 22.5) | 3.8 (0.24) | 0.92 |
| Alcohol (drinks/typical week) § | 1.0 (0, 2) | 1.0 (0, 2) | 1.0 (0,2) | 0.0001 |
| Systolic Blood Pressure | 0.34 | |||
| < 140 mmHg b | 55.4 | 56.1 | 53.9 | |
| 140 – 160 mmHg b | 36.8 | 36.9 | 36.8 | |
| >160 mmHg b | 7.7 | 7.0 | 9.3 | |
| Antihypertension Medications | ||||
| Use of Beta-Blockers b | 31.1 | 30.6 | 32.2 | 0.57 |
| Use of Diuretics b | 42.2 | 41.8 | 43.2 | 0.63 |
| Use of Calcium Channel Blockers b | 35.0 | 34.4 | 36.2 | 0.54 |
| Use of Angiotensin Converting Enzyme Inhibitors b | 40.6 | 40.0 | 42.0 | 0.52 |
| Use of Angiotensin Receptor Blockers b | 17.2 | 17.5 | 16.6 | 0.69 |
| Total Number of Antihypertensive Medications a | 1.8 (1.0) | 1.8 (1.0) | 1.9 (1.0) | 0.22 |
| Cardiometabolic and Psychosocial Variables | ||||
| Glucose (mg/dL) a | 99.4 (12.5) | 99.7 (12.6) | 98.9 (12.4) | 0.33 |
| Diastolic Blood Pressure (mmHg)a | 78.8 (11.8) | 79.9 (11.6) | 76.3 (11.6) | <.0001 |
| Pulse Pressure (mmHg)a, c | 60.2 (13.5) | 58.7 (13.2) | 63.5 (13.5) | <.0001 |
| Total Cholesterol (mg/dL) a | 182.2 (40.4) | 183.8 (39.1) | 178.8 (42.7) | 0.04 |
| Any Anti-Cholesterol Medication b | 54.3 | 51.6 | 60.1 | 0.005 |
| Any Antidepressant Medication b | 11.2 | 11.5 | 10.8 | 0.74 |
| Phosphodiesterase Type 5 Inhibitors b | 10.5 | 13.4 | 4.3 | <.0001 |
| BMI (kg/m2) a | 29.9 (5.5) | 30.2 (5.6) | 29.3 (5.2) | 0.007 |
| eGFR (mL/min/1.73 m2) a | 74.1 (20.6) | 75.9 (19.9) | 70.3 (21.5) | <.0001 |
| Chronic Kidney Disease (eGFR <60 mL/min/1.73m2) a | 19.9 | 34.3 | <.0001 | |
| CVD Family History b | 24.9 | 25.5 | 23.4 | 0.44 |
| MoCA Total Score (range 0 to 30) a, d | 23.1 (3.6) | 23.3 (3.6) | 22.6 (3.7) | 0.0008 |
| PHQ-9 Total Score (range 0 to 27) §, e | 2.0 (0, 4) | 2.0 (0, 5) | 1.0 (0, 4) | 0.011 |
| Number of Physical Comorbidities (range 0 to 32)a, e | 4.3 (2.7) | 4.0 (2.5) | 5.1 (3.0) | <.0001 |
Significant values (p<0.05) are presented in bold
a
Data presented as mean(standard deviation)
§
Data presented as median (25th percentile,75th percentile )
b
Data presented as %
c
defined as (systolic blood pressure in mmHg – diastolic blood pressure in mmHg)
d
Higher scores indicate better function
e
Higher scores indicate poorer function
*
p-value from Chi Square test for categorical variables (b), Student’s t-test for continuous variables with normal distributions (a), and Kruskal-Wallis test for variables with distributions with high skewness or kurtosis (§)